Target intelligence / Profile preview

Alpha,beta-dicarbonyl intermediates of advanced glycation end-product formation (RCS)

Target
RCS
Molecular classification
Reactive metabolite, Small molecule, Dicarbonyl compound
01

Overview

Alpha,beta-dicarbonyl intermediates, such as methylglyoxal (MGO), glyoxal, and 3-deoxyglucosone (3-DG), are highly reactive electrophilic metabolites that serve as the primary precursors for the formation of advanced glycation end-products (AGEs) (PMID: 24508246). These compounds are generated through the Maillard reaction, the polyol pathway, and glycolytic bypass, and they possess a significantly higher glycating potential than glucose itself (PMID: 21115333). Accumulation of these intermediates leads to a state known as dicarbonyl stress, which causes irreversible damage to proteins, DNA, and lipids, contributing to the structural and functional decline of tissues (PMID: 27184158). This process is a central driver in the development of diabetic complications, including nephropathy and retinopathy, as well as age-related conditions like Alzheimer's disease and atherosclerosis (PMID: 15180497). Therapeutic strategies target these intermediates using dicarbonyl scavengers—nucleophilic agents that chemically trap the dicarbonyls to prevent AGE cross-linking (PMID: 26433114). While compounds like aminoguanidine and pyridoxamine have demonstrated efficacy in preclinical models, clinical success has been limited by the need for high specificity to avoid interfering with essential physiological carbonyls like pyridoxal phosphate.

Other names
Reactive dicarbonyl speciesDicarbonyl compoundsAGE precursorsMethylglyoxalGlyoxal3-DeoxyglucosoneReactive carbonyl species
02

Mechanism of action

Chemical scavenging and nucleophilic trapping of reactive dicarbonyl species to inhibit the formation of advanced glycation end-products (AGEs).

03

Biological functions

Protein glycationDNA modificationOxidative stress inductionMaillard reaction intermediate
04

Disease associations

Diabetes mellitusDiabetic nephropathyDiabetic retinopathyCardiovascular diseaseAlzheimer's diseaseAging
05

Safety considerations

Off-target scavenging of essential physiological carbonyls (e.g., Vitamin B6/pyridoxal phosphate)Potential for systemic toxicity and vasculitis (observed with aminoguanidine)Interference with normal regulatory carbonyl signaling
06

Interacting drugs

Aminoguanidine

5 more in the full profile.

07

Biomarkers

Methylglyoxal (MGO)Glyoxal (GO)3-Deoxyglucosone (3-DG)Methylglyoxal-derived hydroimidazolone (MG-H1)N-epsilon-(carboxyethyl)lysine (CEL)

Beyond the preview

Go deeper on Alpha,beta-dicarbonyl intermediates of advanced glycation end-product formation (RCS).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alpha,beta-dicarbonyl intermediates of advanced glycation end-product formation (RCS).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call